Initial Failure of Pristinamycin Treatment in a Case of Multidrug-Resistant Mycoplasma genitalium Urethritis Eventually Treated by Sequential Therapy.
Journal
Sexually transmitted diseases
ISSN: 1537-4521
Titre abrégé: Sex Transm Dis
Pays: United States
ID NLM: 7705941
Informations de publication
Date de publication:
01 11 2021
01 11 2021
Historique:
pubmed:
11
6
2021
medline:
3
11
2021
entrez:
10
6
2021
Statut:
ppublish
Résumé
We present a case of persistent Mycoplasma genitalium urethritis with documented macrolide and fluoroquinolone resistance, and we describe the A2062T mutation in the 23S rRNA gene, possibly associated with pristinamycin resistance. After several treatment failures and loss of the A2062T mutation, M. genitalium urethritis was finally cured by a sequential antibiotic treatment including minocycline.
Identifiants
pubmed: 34110731
pii: 00007435-202111000-00018
doi: 10.1097/OLQ.0000000000001415
doi:
Substances chimiques
Anti-Bacterial Agents
0
Macrolides
0
Pristinamycin
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e163-e164Informations de copyright
Copyright © 2021 American Sexually Transmitted Diseases Association. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of Interest and Sources of Funding: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. The authors received no financial support for the research, authorship, and/or publication of this article.
Références
Jensen JS, Cusini M, Gomberg M, et al. 2016 European guideline on Mycoplasma genitalium infections. J Eur Acad Dermatol Venereol 2016; 30:1650–1656.
Fernández-Huerta M, Barberá MJ, Serra-Pladevall J, et al. Mycoplasma genitalium and antimicrobial resistance in Europe: A comprehensive review. Int J STD AIDS 2020; 31:190–197.
Machalek DA, Tao Y, Shilling H, et al. Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium : A systematic review and meta-analysis. Lancet Infect Dis 2020; 20:1302–1314.
Durukan D, Read TRH, Murray G, et al. Resistance-Guided Antimicrobial Therapy using doxycycline–moxifloxacin and doxycycline–2.5 g azithromycin for the treatment of Mycoplasma genitalium infection: Efficacy and tolerability. Clin Infect Dis 2020; 71:1461–1468.
Read TRH, Fairley CK, Murray GL, et al. Outcomes of resistance-guided sequential treatment of Mycoplasma genitalium infections: A prospective evaluation. Clin Infect Dis 2019; 68:554–560.
Chrisment D, Charron A, Cazanave C, et al. Detection of macrolide resistance in Mycoplasma genitalium in France. J Antimicrob Chemother 2012; 67:2598–2601.
Pereyre S, Guyot C, Renaudin H, et al. In vitro selection and characterization of resistance to macrolides and related antibiotics in Mycoplasma pneumoniae . Antimicrob Agents Chemother 2004; 48:460–465.
Read TR, Fairley CK, Tabrizi SN, et al. Azithromycin 1.5 g over 5 days compared to 1 g single dose in urethral Mycoplasma genitalium : Impact on treatment outcome and resistance. Clin Infect Dis 2017; 64:250–256.
Read TRH, Jensen JS, Fairley CK, et al. Use of pristinamycin for macrolide-resistant Mycoplasma genitalium infection. Emerg Infect Dis 2018; 24:328–335.
Falk L, Jensen JS. Successful outcome of macrolide-resistant Mycoplasma genitalium urethritis after spectinomycin treatment: A case report. J Antimicrob Chemother 2017; 72:624–625.
Doyle M, Vodstrcil LA, Plummer EL, Aguirre I, Fairley CK, Bradshaw CS. Nonquinolone options for the treatment of Mycoplasma genitalium in the era of increased resistance. Open Forum Infect Dis 2020; 7:ofaa291.
Durukan D, Doyle M, Murray G, et al. Doxycycline and sitafloxacin combination therapy for treating highly resistant Mycoplasma genitalium . Emerg Infect Dis 2020; 26:1870–1874.
Le Roy C, Pereyre S, Hénin N, et al. French prospective clinical evaluation of the Aptima Mycoplasma genitalium CE-IVD assay and macrolide resistance detection using three distinct assays. J Clin Microbiol 2017; 55:3194–3200.